COMPLEMENTARY Medicines Australia (CMA) has urged the Government to evaluate whether regulatory reforms under the TGA's Medicines and Medical Devices Review are being "appropriately implemented".
CMA's pre-Budget submission calls on authorities to check that the "policy settings are right," and meeting key objectives of the Review, including cutting red tape and improving timely and safe access to quality therapeutic goods.
CEO Carl Gibson said new legislation introduced last year after the review "sets the regulatory framework for decades to come.
"A health check on the roll-out of the reform implementation is required to ensure that the regulations are fit for purpose and Australia remains competitive on the global stage," he said.
Gibson particularly applauded the implementation of the new approval pathway for listing complementary medicines with higher therapeutic indications and health claims.
He said this measure aimed to "encourage and reward greater investment in research and development by industry and be an incentive to further expand the clinical research base for complementary medicines".
CMA's submission also urges the government to support the growth of Australian exports, focus on preventative health, support investment in research, and restore private health insurance rebates for natural therapies.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Feb 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Feb 19